


Supplementary figure 6



Supplementary figure 6. Ex vivo evaluation of vaccine potency and engraftment of human immune cells in the *in vivo* T cell expansion model. (a) Composition of DC-complete vaccine 1 and 2 used in *in vivo* T cell expansion model 1. (b) Expression of co-stimulatory molecules CD80, CD83 and CD86 on matured DC vaccine before *in vivo* injection. (c) *In vitro* evaluation of functional capacity of respective DC vaccines, used in *in vivo* experiments, to induce expansion of CMV-specific CD8⁺ T cells. (d, e) Percentage of hCD45⁺ cells, CD3⁺ T cells and CD8⁺ T cells in vaccinated mice at day 7 (d) and day 14 (e). (f) Composition of DC-complete vaccine 1 and 2 used in *in vivo* T cell expansion model 2. (g) Expression of co-stimulatory molecules CD80, CD83 and CD86 on matured DC vaccine before *in vivo* injection. (h) *In vitro* evaluation of functional capacity of pan-DC vaccine and DC-complete vaccine, used in *in vivo* experiments, to induce expansion of CMV-specific CD8⁺ T cells. (i, j) Percentage of hCD45⁺ cells, CD3⁺ T cells and CD8⁺ T cells in vaccinated mice at day 7 (i) and day 14 (j). (k-m) *In vivo* engraftment and expansion of hCD45⁺ cells (k), CD3⁺ T cells (l) and CD8⁺ T cells (m) at day 7 and 14. (d, e, i-m) Data is shown as mean $\pm$ SEM (n=8). Statistical analyses were performed using repeated measures one-way ANOVA followed by Bonferroni correction comparing all pairs of columns (d, e), an unpaired T-test (i, j) or a paired T-test (k-m). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.